Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics posts double digit revenue growth

The company expects revenues to be in the order of £31.5mln in the first half of its financial year, which equates to a 12% rise at constant currencies.
Allergy Therapeutics posts double digit revenue growth
The company's products provide vaccines against certain pollens.

Allergy Therapeutics (LON:AGY) said it is gaining market share in all of its major European territories as it gave an upbeat assessment of current trading.

It expects revenues to be in the order of £31.5mln in the first half of its financial year, which equates to a 12% rise at constant currencies.

This solid performance was supported by acquisition of Alerpharma last June.

Chief executive Manuel Llobet told investors: “Overall we are executing our business strategy and, in addition to growing our European business, remain focused on executing a pivotal clinical trial programme, potentially paving the way towards the US and expanding into new market segments with a strong new product pipeline. 

“Our business is now in a very strong position to generate continuing growth over the coming years."

The company has developed a suite of treatments aimed at common pollen allergies that have created a very sound business in Europe.

Analysts reckon a long-term opportunity will come in the States where the company’s flagship product, Pollinex Quattro, is set to hit the market in the next three to four years.

Ian_55ae0ddd437b7.jpg
Why Invest In Allergy Therapeutics plc? Read More Here

Register here to be notified of future AGY Company articles
View full AGY profile

Allergy Therapeutics plc Timeline

Newswire
October 10 2016

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
shutterstock_234586750.jpg
Wed
N+1, in a note to clients, described the financial performance as “solid”, which perhaps understated Abzena’s progress in the six months to September 30.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.